肿瘤坏死因子受体超家族成员 4（TNFRSF4）基因表达在急性髓系白血病的诊断和预后中的作用。
The role of tumor necrosis factor receptor superfamily member 4 (TNFRSF4) gene expression in diagnosis and prognosis of acute myeloid leukemia.
机构信息
Clinical Pathology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
出版信息
Mol Biol Rep. 2021 Oct;48(10):6831-6843. doi: 10.1007/s11033-021-06682-6. Epub 2021 Aug 28.
OBJECTIVES
Acute myeloid leukemia (AML) is still challenging in predicting the prognosis due to its high heterogeneity. Molecular aberrations and abnormalities play a significant prognostic role in AML patients. Our aim of the study was to investigate the prognostic role of TNFRSF4 gene expression in AML patients and its potential effect on treatment protocols.
METHODS
Bone marrow mononuclear cells were analyzed for TNFRSF4 expression by real-time quantitative PCR as well as of FLT3/ITD and NPM1 mutations in 80 newly diagnosed AML patients and 80 control subjects.
RESULTS
TNFRSF4 was significantly overexpressed in the AML patients (p < 0.001). TNFRSF4 expression was associated with unfavorable clinical outcomes including treatment response, relapse free survival, and overall survival. On multivariate testing, TNFRSF4 high expression proved to be an independent prognostic marker for clinical remission and relapse free survival but not overall survival.
CONCLUSION
TNFRSF4 expression was revealed as an unfavorable prognostic marker and might be a target for immunotherapy in the future.
目的
由于急性髓系白血病（AML）具有高度异质性，因此在预测预后方面仍然具有挑战性。分子异常和畸变在 AML 患者的预后中起着重要作用。本研究旨在探讨 TNFRSF4 基因表达在 AML 患者中的预后作用及其对治疗方案的潜在影响。
方法
通过实时定量 PCR 分析 80 例新诊断的 AML 患者和 80 例对照骨髓单个核细胞中 TNFRSF4 的表达，以及 FLT3/ITD 和 NPM1 突变。
结果
TNFRSF4 在 AML 患者中显著过表达（p<0.001）。TNFRSF4 表达与不良临床结局相关，包括治疗反应、无复发生存和总生存。多变量检验表明，TNFRSF4 高表达是临床缓解和无复发生存的独立预后标志物，但不是总生存的独立预后标志物。
结论
TNFRSF4 表达被揭示为不良预后标志物，将来可能成为免疫治疗的靶点。
Zotero 插件